Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials.

Mount DL, Feeney P, Fabricatore AN, Coday M, Bahnson J, Byington R, Phelan S, Wilmoth S, Knowler WC, Hramiak I, Osei K, Sweeney ME, Espeland MA, Look AHEAD and ACCORD Research Groups

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L, DURATION-1 Study Group

An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update).

Philis-Tsimikas A

Improving treatment of depression among Latinos with diabetes using project Dulce and IMPACT.

Gilmer TP, Walker C, Johnson ED, Philis-Tsimikas A, Unützer J

Effects of intensive glucose lowering in type 2 diabetes.

Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT

Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes.

Philis-Tsimikas A

Cost-effectiveness of diabetes case management for low-income populations.

Gilmer TP, Roze S, Valentine WJ, Emy-Albrecht K, Ray JA, Cobden D, Nicklasson L, Philis-Tsimikas A, Palmer AJ

Prevalence of sleep apnea in a population of adults with type 2 diabetes mellitus.

Einhorn D, Stewart DA, Erman MK, Gordon N, Philis-Tsimikas A, Casal E

Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.

Karl D, Philis-Tsimikas A, Darsow T, Lorenzi G, Kellmeyer T, Lutz K, Wang Y, Frias JP

Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program.

Philis-Tsimikas A, Zhang Q, Walker C